Gain Therapeutics, Inc. GANX
Set alert
As of Nov 2, 2:19 PM ET
- YTD
- -64.91%
- 1 year
- -42.35%
- Open
- 1.15
- Prev close
- 1.13
- Mkt cap
- 49.32M
- Vol
- 195.69K
- Avg vol
- 503.88K
- EPS
- -0.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.13
- High
- 1.20
- Forward P/E
- -1.76
- Beta
- 0.34
- Short ratio
- 1.65
- Inst. own
- 7.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.05
- 200-d avg
- 2.12
- 1y target
- 7.33
News
2 weeks ago globenewswire.com
Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial…
3 weeks ago globenewswire.com
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
-
4 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
-
1 month ago benzinga.com
Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule
1 month ago globenewswire.com
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration…
-
1 month ago benzinga.com
Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule
1 month ago globenewswire.com
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
1 month ago defenseworld.net
Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison
Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
1 month ago globenewswire.com
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
2 months ago globenewswire.com
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
-
2 months ago benzinga.com
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of…
-
3 months ago benzinga.com
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has…
3 months ago globenewswire.com
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock…
-
4 months ago benzinga.com
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy…
4 months ago globenewswire.com
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26
4 months ago globenewswire.com
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
5 months ago globenewswire.com
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph…
5 months ago globenewswire.com
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
-
6 months ago benzinga.com
Gain Therapeutics To Give Oral Presentation Update On GCase Modulator For Parkinson's Disease At 3rd International GBAI Meeting May 22-23
Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant…
6 months ago globenewswire.com
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
-
7 months ago benzinga.com
Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is unchanged from the same period last year.
7 months ago globenewswire.com
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
7 months ago defenseworld.net
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics (NASDAQ: GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside…
7 months ago globenewswire.com
Gain Therapeutics to Present at the 38th Annual ROTH Conference
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
Gain Therapeutics Presents Poster At AD/PD 2026 International Conference on Alzheimer's And Parkinson's Disease And Related Neurological Disorders On New Clinical, Biomarket Data From Phase 1B Clinical Trial Of GT-02287
Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule…
7 months ago globenewswire.com
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals…
7 months ago defenseworld.net
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next?
Gain Therapeutics, Inc. (NASDAQ: GANX - Get Free Report) shot up 3.7% on Monday. The stock traded as high as $2.63 and last traded at $2.52. 561,330 shares changed hands during trading, a decline of…
7 months ago globenewswire.com
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of…
8 months ago globenewswire.com
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
10 months ago benzinga.com
Gain Therapeutics Reports Early Parkinson's Trial Results, Drug Cuts Disease Marker by 81% in Early Gain Therapeutics Study
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule…
10 months ago benzinga.com
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
10 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
10 months ago benzinga.com
Gain Therapeutics Reports Early Parkinson's Study Showing Brain Biomarker Improvement After 90 Days Of Treatment
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule…
-
11 months ago benzinga.com
Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 7.41 percent. This is a 11.76 percent increase over losses of…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
-
1 year ago benzinga.com
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
Maxim Group analyst Jason McCarthy maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and raises the price target from $5 to $7.
-
1 year ago benzinga.com
Gain Therapeutics Presents Phase 1b GT-02287 Data At International Congress Of Parkinson's Disease And Movement Disorders, Highlighting Safety, Tolerability, And Exploratory Findings In PD Patients With or Without GBA1 Mutation
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participantsPlasma exposures in patients within projected therapeutic range and…
-
1 year ago benzinga.com
Gain Therapeutics Begins GT-02287 Phase 1b Extension Study Allowing Participants To Continue Treatment For Additional Nine Months
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing scheduleThe Phase 1b study enrolled 21…
-
1 year ago benzinga.com
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.
-
1 year ago benzinga.com
Roth Capital Maintains Buy on Gain Therapeutics, Lowers Price Target to $6
Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $7 to $6.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed.
1 year ago benzinga.com
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket